Results 1 to 10 of about 896 (150)

Nemolizumab for the treatment of atopic dermatitis

Journal of Dermatological Treatment
Purpose Atopic dermatitis (AD) is a common, heterogeneous inflammatory skin disease characterized by chronic or relapsing eczematous lesions and intense pruritus, leading to reduced quality of life and increased mental health burden.
Raj Chovatiya, Torres T
exaly   +5 more sources

Clinical factors predicting nemolizumab response in atopic dermatitis

Journal of Allergy and Clinical Immunology: Global
Clinical predictors of response to nemolizumab, an anti-IL-31 receptor A antibody, were evaluated in patients with atopic dermatitis (AD). In a retrospective study of 14 Japanese patients, longer disease duration was significantly associated with poor ...
Yu Sawada, Kenji Kabashima, Satoru Yonekura   +2 more
exaly   +5 more sources

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis [PDF]

Journal of the European Academy of Dermatology and Venereology
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Laurent Misery, Curdin Conrad, Martin Metz   +2 more
exaly   +3 more sources

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Acta Dermato-Venereologica
Nemolizumab with background topical therapy (corticosteroids±calcineurin inhibitors) significantly improved skin lesions, itch and sleep in two global phase 3 trials (ARCADIA 1&2) in adolescents and adults with moderate-to-severe atopic dermatitis ...
Andreas Wollenberg, Jonathan I. Silverberg, Franz J. Legat, Marie Tauber, Vivian T. Laquer, April W. Armstrong, Andrew E. Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty   +19 more
doaj   +2 more sources

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis [PDF]

Dermatology and Therapy
Prurigo nodularis (PN) is a chronic skin condition characterized by severe, persistent pruritus and impairment in health-related quality of life. Dupilumab and nemolizumab are the only treatments approved by the US Food and Drug Administration and the ...
Gil Yosipovitch, Katarzyna Borkowska, James Frampton, Kassandra Schaible, Marissa Betts, Katrin Jack, Zarif Jabbar Lopez, Binod Neupane, Christophe Piketty, Ramkumar Subramanian, Jorge Puelles Fernández de Trocóniz   +10 more
doaj   +2 more sources

Acquired reactive perforating collagenosis treated with nemolizumab [PDF]

JAAD Case Reports
Shehani T. Perera, BS, Sofia Vescovacci, BS, Sara Kaye Givens, PA, Marc Inglese, MD, András Schaffer, MD, PhD, Austinn Miller, MD   +5 more
doaj   +5 more sources

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Journal of Dermatological Treatment, 2023
Background Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies.
Kenji Kabashima, Makoto Kawashima, Takayo Matsumura   +2 more
exaly   +2 more sources

Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials [PDF]

Dermatology and Therapy
Introduction Nemolizumab is a humanized monoclonal antibody that specifically inhibits the receptor for interleukin-31, the major pruritogen in atopic dermatitis (AD).
Makoto Kawashima, Tomoya Maeda, Kotaro Iwasaki, Masashi Takizawa, Noriaki Kaneda, Kenji Kabashima   +5 more
doaj   +2 more sources

Safety and Efficacy of Nemolizumab for Patients with Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trial

Frontiers in Immunology, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Xiaojing Kang, Yingbing Sang, Yongzhen Hong   +2 more
exaly   +3 more sources

Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a complex disease with clinical heterogeneity. Nemolizumab is a novel interleukin (IL)-31 receptor alpha inhibitor that has demonstrated efficacy in managing moderate-to-severe AD. However, there are no head-to-head
Andrew E. Pink, John Houghton, Holly White, Sofia Schiavo, Christophe Piketty, Liliana Ulianov, Rajesh Rout, Katrin Jack, Ramkumar Subramanian, Jorge Puelles   +9 more
doaj   +2 more sources